These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34355175)

  • 1. A review of the latest research on M
    Yang H; Yang J
    RSC Med Chem; 2021 Jul; 12(7):1026-1036. PubMed ID: 34355175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.
    Wang YC; Yang WH; Yang CS; Hou MH; Tsai CL; Chou YZ; Hung MC; Chen Y
    Am J Cancer Res; 2020; 10(8):2535-2545. PubMed ID: 32905393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease.
    Joshi RS; Jagdale SS; Bansode SB; Shankar SS; Tellis MB; Pandya VK; Chugh A; Giri AP; Kulkarni MJ
    J Biomol Struct Dyn; 2021 Jun; 39(9):3099-3114. PubMed ID: 32329408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus.
    Zhang Y; Gao H; Hu X; Wang Q; Zhong F; Zhou X; Lin C; Yang Y; Wei J; Du W; Huang H; Zhou H; He W; Zhang H; Zhang Y; McCormick PJ; Fu J; Wang D; Fu Y; Lu X; Zhang T; Duan J; Qin B; Jiang H; Luo J; Zhang Y; Chen Q; Luo Q; Cheng L; Zhang Z; Zhang J; Li J
    J Virol; 2022 Jan; 96(1):e0125321. PubMed ID: 34586857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of potential inhibitors targeting non-structural proteins 3 (PL
    Yan F; Gao F
    Comput Struct Biotechnol J; 2021; 19():4868-4883. PubMed ID: 34457214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insect protease inhibitors; promising inhibitory compounds against SARS-CoV-2 main protease.
    Hemmati SA; Tabein S
    Comput Biol Med; 2022 Mar; 142():105228. PubMed ID: 35051855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease.
    Mahdi M; Mótyán JA; Szojka ZI; Golda M; Miczi M; Tőzsér J
    Virol J; 2020 Nov; 17(1):190. PubMed ID: 33243253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors.
    Ma C; Hu Y; Townsend JA; Lagarias PI; Marty MT; Kolocouris A; Wang J
    bioRxiv; 2020 Sep; ():. PubMed ID: 32995786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library.
    Shahhamzehei N; Abdelfatah S; Efferth T
    Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.
    Gimeno A; Mestres-Truyol J; Ojeda-Montes MJ; Macip G; Saldivar-Espinoza B; Cereto-Massagué A; Pujadas G; Garcia-Vallvé S
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity.
    Weng YL; Naik SR; Dingelstad N; Lugo MR; Kalyaanamoorthy S; Ganesan A
    Sci Rep; 2021 Apr; 11(1):7429. PubMed ID: 33795718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300.
    Davis DA; Bulut H; Shrestha P; Yaparla A; Jaeger HK; Hattori SI; Wingfield PT; Mieyal JJ; Mitsuya H; Yarchoan R
    mBio; 2021 Aug; 12(4):e0209421. PubMed ID: 34399606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
    Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M
    Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
    Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
    J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19.
    Steuten K; Kim H; Widen JC; Babin BM; Onguka O; Lovell S; Bolgi O; Cerikan B; Neufeldt CJ; Cortese M; Muir RK; Bennett JM; Geiss-Friedlander R; Peters C; Bartenschlager R; Bogyo M
    ACS Infect Dis; 2021 Jun; 7(6):1457-1468. PubMed ID: 33570381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.